Topoisomerase inhibitors

Topoisomerase inhibitors

FOR MAY EXAM 4M 03/18

FOR MAY EXAM 4M 03/18

Disorders of fatty acid metabolism: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Pyramidal and extrapyramidal tracts
Ascending and descending spinal tracts
Muscle spindles and golgi tendon organs
Somatosensory pathways
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Heparin-induced thrombocytopenia
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Opioid antagonists
Antimetabolites for cancer treatment
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Platinum containing medications
Topoisomerase inhibitors
Ribonucleotide reductase inhibitors
Opioid agonists, mixed agonist-antagonists and partial agonists
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
Adrenergic antagonists: Beta blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Cardiac conduction system
Cardiac conduction velocity
ECG basics
ECG rate and rhythm
ECG intervals
ECG QRS transition
ECG axis
ECG normal sinus rhythm
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Nonbenzodiazepine anticonvulsants
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Extrinsic hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Premature ventricular contraction
Premature atrial contraction
Atrial fibrillation
Atrial flutter
Atrioventricular nodal reentrant tachycardia (AVNRT)
Wolff-Parkinson-White syndrome
Atrioventricular block
Bundle branch block
Long QT syndrome and Torsade de pointes
Ventricular tachycardia
Brugada syndrome
Ventricular fibrillation
Pulseless electrical activity
ECG cardiac hypertrophy and enlargement
ECG cardiac infarction and ischemia
Electrolyte disturbances: Pathology review
Postoperative evaluation: Clinical
Mesothelioma
Lung cancer and mesothelioma: Pathology review
Diffuse parenchymal lung disease: Clinical
Lung cancer: Clinical
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Restrictive lung diseases: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Sympathomimetics: Direct agonists
Muscarinic antagonists
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Arsenic poisoning
Cyanide poisoning
Lead poisoning
Methemoglobinemia
Ethylene glycol poisoning
Mercury poisoning
Paracetamol toxicity
Serotonin syndrome
Neuroleptic malignant syndrome
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Pneumothorax
Pneumothorax: Clinical
Chest trauma: Clinical
Pleural effusion: Clinical
Ehlers-Danlos syndrome
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Thoracic wall
Anatomy clinical correlates: Pleura and lungs
Anatomy clinical correlates: Mediastinum
Shock: Clinical

Transcript

Watch video only

Topoisomerase inhibitors, as their name implies, are a class of medications that act by blocking an enzyme called topoisomerase.

They are mainly used as anticancer agents that target specific phases of the cell cycle.

An interesting fact about these agents is that they are natural products, meaning they are extracted from roots, plants, or trees.

But first things first.

The cell cycle refers to the events that somatic cells - which includes all of the cells in our bodies except the reproductive cells - go through from the moment they’re formed until the moment they divide into two identical daughter cells.

This cycle varies in length depending on the type of cell.

For rapidly dividing cells, like skin cells, it takes less than a day, whereas for other cells, like liver cells, the cell cycle can last for years.

Now, the cell cycle can be divided into two phases: interphase and mitosis.

Interphase comprises of the G1 phase, during which the cell grows and performs its functions, the S phase, during which DNA is replicated, and the G2 phase, during which the cell grows again before entering mitosis, or the M phase.

Mitosis can be broken down into prophase, metaphase, anaphase, and telophase, during which the replicated DNA divides equally for the two daughter cells, and ends with cytokinesis, which is when the cell membrane actually divides to form the two new cells.

Okay, so during DNA replication, we unzip the double helix with the enzyme DNA helicase and this creates a replication fork, with the two prongs of the fork represented by the two strands that are separated from one another.

Now, as DNA helicase unzips the DNA, the segments of DNA ahead of it start to overwind - meaning, the double helix becomes more tightly wound.

Overwinding of the DNA can slow down replication, so the enzyme DNA topoisomerase works ahead of DNA helicase to loosen up the tight DNA coils.

It achieves this by gently snapping one strand, loosening the overwinding tension, and then patching it back up, tension free.

Okay, so topoisomerase inhibitors are meant to interfere with both types of DNA topoisomerases, called topoisomerase I and II.

Topoisomerase I cuts one of the two strands of the double-stranded DNA during replication, while Topoisomerase II cuts both strands.

If we disable these enzymes, DNA will overwind just like a rubber band, until it tears itself apart, leading to cell death.

Since cancer cells, in general, proliferate faster than healthy cells, they undergo DNA replication more frequently and are more prone to the DNA damage caused by topoisomerase inhibitors.

Alright, now topoisomerase inhibitors are cell cycle-specific, or CCS, agents, and they are the most active during the late S and early G2 phases of the cell cycle.

Okay, let’s start with camptothecins like irinotecan and topotecan, which are isolated from the stems of the Camptotheca tree, also called happy tree, cancer tree, or tree of life.

They bind to and inhibit topoisomerase I and cause DNA damage during replication, leading to cell death.

Irinotecan is a prodrug, meaning that it needs to be metabolized into an active form within the liver before it can produce the desired effect.

In terms of elimination, irinotecan is excreted through bile and feces, while topotecan is excreted through the kidneys, so the dose should be reduced in people with impaired renal function.

Now, irinotecan is used in metastatic colon cancer; and topotecan is used for the treatment of advanced ovarian cancer and for small cell lung cancer.

The two most common side effects are myelosuppression, or depression of the bone marrow function and gastrointestinal problems like diarrhea, which is more common with irinotecan, but in general, these medications have fewer toxicities than most other anticancer agents.

Alright, next we have the podophyllotoxins like etoposide and teniposide, which are derived from mandrake root, or Podophyllum peltatum.

These medications induce DNA breakage through the inhibition of topoisomerase II.

Elimination of teniposide and etoposide is mainly through the kidneys, which again means that the dosage needs to be reduced in people with renal problems.

Moving on to the indications, these agents are used in: solid tumors, particularly in testicular and small cell lung cancer; in leukemia, which is a type of blood cancer primarily affecting stem cells in the bone marrow; and in lymphomas, which usually derive from lymphocytes in the lymph nodes.

Key Takeaways

Topoisomerase inhibitors are a group of medications used in cancer chemotherapy that target the enzyme called DNA topoisomerase I or II, which is involved in DNA replication and transcription.

Topoisomerase inhibitors work by preventing the enzyme from unwinding DNA strands during replication or transcription, which leads to the accumulation of DNA damage and cell death. Examples include irinotecan and topotecan which inhibit topoisomerase I; and etoposide and teniposide which inhibit topoisomerase II.

Topoisomerase inhibitors are used to treat various types of cancer, such as colon cancer, leukemia, ovarian, and small-cell lung cancer. Common side effects of topoisomerase inhibitors include fatigue, gastrointestinal problems like diarrhea, hair loss, anemia, and increased risk of infection. Some patients may also experience more severe side effects, such as cardiac toxicity or secondary malignancies.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Nomograms" D. Nicoll , C. Mark Lu, S.J. McPhee (Eds.), Guide to Diagnostic Tests, 7e. McGraw-Hill (2017)
  5. "Overview of hemostasis" J.C. Aster, H. Bunn (Eds.), Pathophysiology of Blood Disorders, 2e. McGraw-Hill. (2016)
  6. "Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules" Cancers (2018)
  7. "Formation and biological targets of botanical o-quinones" Food and Chemical Toxicology (2018)